Compare Moderna, Inc. (MRNA) vs Nebius Group NV (NBIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Nebius Group NV — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Nebius Group NV trades at $221.12 (market cap $59.73B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Moderna, Inc. is trading nearer its 52-week high, Nebius Group NV nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Nebius Group NV for 24 Days on average.
| MRNA | NBIS | |
|---|---|---|
Market Cap | $78.65B | $59.73B |
Volume | 37,373,437 | 21,563,700 |
Sector | Health | Technology |
52-Week High | $225.00 | $286.69 |
52-Week Low | $22.36 | $73.87 |
Typical Hold Time | 59 Days | 24 Days |
Enterprise Value | $74.80B | $61.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.
The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.
NBIS trades at $219.71, down 7.32% over 24 hours amid bearish technical signals. The stock shows mixed fundamentals with strong revenue growth projections ($530M in 2025 to $1.4B in 2026) but thin net margins (3.13%) and elevated valuations (P/E 845). Recent earnings beat expectations in Q1 and Q2 2026, while analyst sentiment remains overwhelmingly bullish with 82% buy ratings and a $288.67 consensus target.
The outlook balances high-growth AI infrastructure demand against execution risks and rich valuations. Near-term support lies at $214, with upside potential to $288 if operational scaling continues. Key risks include competitive pressure, heavy capital expenditure, and insider selling activity noted in recent filings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →
